Biotricity (OTC: BTCY) is in a growth-to-profitability transition phase, leveraging AI-driven automation and subscription-based cardiac diagnostics to expand margins and scale. The company’s positive EBITDA, recurring revenue dominance, and free cash flow stability position it for potential near-term profitability.
Totally agree. It’s going to be interesting to see if the company can get to profitability without having to raise money again. I remember when I talked to management around five or six years ago. Profitability was supposed to be around the corner without significant dilution … and as you know… they’ve diluted a lot since then.
Totally agree. It’s going to be interesting to see if the company can get to profitability without having to raise money again. I remember when I talked to management around five or six years ago. Profitability was supposed to be around the corner without significant dilution … and as you know… they’ve diluted a lot since then.